Form 4: Tenaya Therapeutics Director June Lee Granted 107,400 Stock Options

Tenaya Therapeutics, Inc. Director June Lee was granted 107,400 stock options with an exercise price of $0.4444, vesting in May 2026 or earlier.

Summary

• June Lee, a Director of Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options.
• The transaction date for this grant was May 29, 2025.
• The exercise price for these stock options is $0.4444 per share.
• The options will vest in full on May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date.
• Vesting is contingent upon Ms. Lee continuing to be a service provider to Tenaya Therapeutics through each applicable vesting date.
• The options were granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.
• The expiration date for these options is May 28, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally a neutral to slightly positive event as it aligns director interests with shareholders. There are no negative implications or unexpected outcomes reported.

Positives

• The grant of stock options to Director June Lee aligns her financial interests with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of the company's established 2021 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it primarily reports a routine compensation event.

Risks

• The value of the granted stock options is dependent on the future market price of Tenaya Therapeutics' common stock, posing a market risk to the recipient.
• Vesting of the options is subject to the reporting person's continued service to the issuer, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

This Form 4 primarily details a past transaction and its future vesting schedule. It indicates that the granted stock options will vest in full by May 29, 2026, or earlier, contingent on the director's continued service.

Industry Context

This Form 4 reports an individual insider transaction, specifically a stock option grant to a director. Such grants are a common form of compensation in the biotechnology and pharmaceutical industries, used to attract and retain talent and align management interests with long-term shareholder value. The specific details of the grant (exercise price, vesting schedule) are typical for equity incentive plans in the sector.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, which includes a one-year cliff or earlier vesting tied to the next annual meeting, is a common structure designed to ensure continued service and align with corporate governance cycles.
• The exercise price being relatively low ($0.4444) suggests these are likely incentive stock options or non-qualified stock options granted at or near the fair market value on the grant date, a typical approach for equity compensation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director June Lee constitutes a transaction between the company and a related party (an insider), which is a standard form of compensation.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's interests with those of the shareholders, potentially leading to better long-term performance and value creation.
• Employees (specifically the director): The options serve as a form of compensation and incentive for continued service and performance.

Next Steps

• The granted stock options will vest in full on May 29, 2026, or the day immediately before the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, June Lee, Stock Options, Form 4, SEC Filing, Insider Transaction, Equity Incentive Plan, Director Compensation, Biotechnology, Pharmaceuticals